Latest from Siteman

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.
Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses frontline therapy selection in chronic lymphocytic leukemia (CLL).
Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.
Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.
Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses exciting data on the horizon in chronic lymphocytic lymphoma (CLL).
Stephen Oh, MD, PhD, discusses the use of ruxolitinib in patients with myelofibrosis and polycythemia vera, and emerging agents and next steps in the field of myeloproliferative neoplasms.
Geoffrey Uy, MD, discusses the impact of targeted therapies on the treatment of patients with newly diagnosed acute myeloid leukemia.
Ravi Vij, MD, discusses emerging treatment options for patients with newly diagnosed multiple myeloma.
Publication Bottom Border
Border Publication
x